Pharming Group NV
http://www.pharming.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Pharming Group NV
Less Than First: Below-Average Innovation In US FDA’s Big 2023 Novel Approval Haul
Innovation metrics like first-in-class and breakthrough therapy approvals declined as a share of novel agents in 2023, even as the US FDA’s drugs center posted one of its biggest novel approval totals ever.
Keeping Track: Pfizer And J&J’s Dueling Myeloma Bispecifics; Regeneron And Ipsen Nab Priority Vouchers
Shared REMS, diverse confirmatory trials and manufacturing delays are among the highlights in the latest US FDA drug approval news from the Pink Sheet’s US FDA Performance Tracker.
Pharming Pleased With Joenja Launch
The Dutch biotech says it has made good progress globally in identifying the patients who could benefit from Joenja, its recently approved treatment for activated phosphoinositide 3-kinase delta syndrome.
Keeping Track: Pharming’s Joenja, Cidara’s Rezzayo And Incyte’s Zynyz Headline US FDA Approval Bonanza
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice